Economic evaluation of rivaroxaban in stroke prevention for patients with atrial fibrillation in Greece

Kourlaba, Georgia; Maniadakis, Nikos; Andrikopoulos, George; Vardas, Panos

doi:10.1186/1478-7547-12-5

Cost Effectiveness and Resource Allocation

Table 1 Event rates and relative risks of clinical events for each therapy

From: Economic evaluation of rivaroxaban in stroke prevention for patients with atrial fibrillation in Greece

	3-month baseline rate	Sources
Ischemic stroke
VKA	0.40%	ROCKET AF [15] ^§
Myocardial infarction
VKA	0.28%	ROCKET AF [15] ^§
Systemic embolism
VKA	0.05%	ROCKET AF [15] ^§
Intracranial bleeding
VKA	0.19%	ROCKET AF [15] ^§
Minor extracranial bleeding
VKA	2.97%	ROCKET AF [15] ^§
Major extracranial bleeding
VKA	0.69%	ROCKET AF [15] ^§
	RR (95% CI)	Sources
Ischemic stroke
Rivaroxaban vs. VKA (SOT)	0.94 (0.75 – 1.17)	ROCKET AF [18]
Rivaroxaban vs. VKA (ITT)	0.99 (0.82 – 1.20)	ROCKET AF [15]
Myocardial infarction
Rivaroxaban vs. VKA (SOT)	0.81 (0.63 – 1.06)	ROCKET AF [15]
Rivaroxaban vs. VKA (ITT)	0.91 (0.72 – 1.16)	ROCKET AF [15]
Systemic embolism
Rivaroxaban vs. VKA (SOT)	0.23 (0.09 – 0.61)	ROCKET AF [18]
Rivaroxaban vs. VKA (ITT)	0.74 (0.42 – 1.32)	ROCKET AF [15]
Intracranial bleeding
Rivaroxaban vs. VKA	0.67 (0.47 – 0.93)	ROCKET AF [15] ^§
Major extracranial bleeding
Rivaroxaban vs. VKA	1.14 (0.98 – 1.33)	ROCKET AF [18] ^§
Minor extracranial bleeding
Rivaroxaban vs. VKA	1.04 (0.96 – 1.13)	ROCKET AF [15] ^§
	Mortality rates ^¶	Sources
Stroke related
Case fatality of major stroke	12.6%	ROCKET AF [15]
Case fatality of minor stroke	0.00%	Assumption
Post-major stroke mortality rate	2.60%	Marini et al. 2005 [19]
Post-minor mortality rate	0.00%	Assumption
Bleeding-related
Case-fatality of major bleed	1.60%	ROCKET AF [15]
Case-fatality of minor bleed	0.00%	Assumption
Case-fatality of intracranial bleed	38.80%	ROCKET AF [15]
Post- major bleed mortality rate	0.00%	Assumption
Post- minor bleed mortality rate	0.00%	Assumption
Post- Intracranial bleed mortality rate	2.60%	Assumption (equal to stroke)
Systemic embolism-related
Case-fatality of systemic embolism	0.00%	Eckman 1992 [20]
MI-related
Case-fatality rate of myocardial infarction	9.69%	ROCKET AF [15]
Post myocardial infarction mortality rate	2.68%	Hoit et al. 1986 [21]

SOT safety on treatment, ITT Intention-to-Treat, VKA vitamin-K-antagonist.
^¶based on the sum of case fatality rates in both arms of the ROCKET trial.
^§Data derived from safety on treatment analysis of ROCKET trial.

Back to article page

ISSN: 1478-7547

Contact us

General enquiries: journalsubmissions@springernature.com